DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. (Q39538214)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

0 references

Christian H. Ottensmeier

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Gisella E Vittes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Elena L Harden

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Jason Rice

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

4 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

2447-2456

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21604260%20AND%20SRC:MED&resulttype=core&format=json

Natural history of progression after PSA elevation following radical prostatectomy

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Prostate cancer as a model for tumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

DNA vaccines for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

DNA vaccines: precision tools for activating effective immunity against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

HLA class I transgenic mice: development, utilisation and improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Clearance of Theiler's virus infection depends on the ability to generate a CD8+ T cell response against a single immunodominant viral peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

DNA vaccines against cancer come of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

FOXP3+ regulatory T cells in the human immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Electropermeabilization of skeletal muscle enhances gene transfer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in p

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

7 January 2021

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

7 January 2021

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

7 January 2021

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

7 January 2021

Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

7 January 2021

Critical Components of a DNA Fusion Vaccine Able to Induce Protective Cytotoxic T Cells Against a Single Epitope of a Tumor Antigen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

7 January 2021

DNA Fusion Vaccine Designed to Induce Cytotoxic T Cell Responses Against Defined Peptide Motifs: Implications for Cancer Vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

7 January 2021

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

7 January 2021

DNA Fusion Vaccines Induce Epitope-Specific Cytotoxic CD8+ T Cells against Human Leukemia-Associated Minor Histocompatibility Antigens

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141518

7 January 2021